Genentech, Inc.;Board of Regents, The University of Texas System
发明人:
Mark Merchant,Deepak Sampath,Marina Konopleva,Lina Han
申请号：
US15767914
公开号：
US20180303815A1
申请日:
2016.11.03
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
